Answers are grounded in this paper and cite their sources.
Objective: Cancer-related fatigue (CRF) is the most common side effect associated with both cancer and its treatment. There are several screening tools for CRF, but their concordance remains largely unclear. Therefore, the study aimed to compare different existing screening tools and how they relate to validated CRF assessments.Methods: 338 patients with different types of cancer were analyzed. Three different screening tools for CRF (‘Energy Scale’, ‘Cella Screening’, and the ‘Impact Scale’) were applied and compared with validated fatigue measures (Cella Criteria, EORTC QLQ-FA12). The assessments were compared cross-sectionally at three timepoints during the first 12 weeks after study inclusion.Results: When comparing the three different screening tools, we found that they resulted in different numbers of patients being screened positive for CRF and therefore potentially requiring further diagnostics. Regarding the Energy Scale, 87.5% of negatively screened patients were classified as not fatigued by the Cella Criteria, but approximately half of positively screened patients were classified as ‘false positive’. The Impact Scale discriminated best between fatigued/non-fatigued patients when compared to the Cella Criteria. Comparing all screening tools with the FA12, the vast majority of patients who screened positive had higher FA12 scores. The level of concordance remained similar at all timepoints.Conclusions: There appear to be differences in the ability of existing screening tools to discriminate between fatigued/non-fatigued patients. The Impact Scale seems to provide the most valid indication of a patient’s CRF status.Trial registration: ClinicalTrials.gov identifier: NCT05448573..
No takes yet. Share an insight, caveat, or question.
Blickle et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: